Lilly sees surging sales in contrast to obesity rival Novo
The guidance was a sharp contrast to rival Novo Nordisk A/S, which warned investors Tuesday that its sales could drop as much as 13% this year on intensifying price competition in the weight loss market
The guidance was a sharp contrast to rival Novo Nordisk A/S, which warned investors Tuesday that its sales could drop as much as 13% this year on intensifying price competition in the weight loss market
What's Your Reaction?
DDP Editor
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
